Study In Patients With Insulin Resistance
This study has been completed.
Information provided by:
First received: September 14, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
Fluid management study in patients with insulin resistance.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Single-Centre, Randomised, Double-Blind, Placebo Controlled, Two 12 Week Period, Cross-Over Phase III Study to Investigate the Effect of Rosiglitazone 4mg Bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Forearm blood flow
Secondary Outcome Measures:
- Insulin sensitivity, plasma volume, transcapillary escape rate, inhibition to vasodialtory response, changes in cardiac output, plasma catecholamine levels, changes in plasma hormone/markers of vascular permeability, safety and tolerability.
|Study Start Date:||October 2002|
Contacts and Locations